{"title_page": "LY-404187", "text_new": "{{Drugbox\n| Verifiedfields = changed\n| Watchedfields = changed\n| verifiedrevid = 449869240\n| IUPAC_name = ''N''-[2-(4'-cyanobiphenyl-4-yl)propyl]propane-2-sulfonamide\n| image = LY404187.png\n| width = 250px\n\n<!--Clinical data-->\n| tradename = \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B / C / D / X -->\n| pregnancy_category = \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = <!-- Schedule I -->\n| legal_UK = <!-- Class A -->\n| legal_US = Investigational New Drug\n| legal_status = \n| routes_of_administration = \n\n<!--Pharmacokinetic data-->\n| bioavailability = \n| protein_bound = \n| metabolism = \n| excretion = \n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 211311-95-4\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 75W6I8W6OU\n| ATC_prefix = none\n| ATC_suffix = \n| PubChem = \n| DrugBank_Ref = {{drugbankcite|correct|drugbank}}\n| DrugBank = \n| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = 18962921\n\n<!--Chemical data-->\n| C=19 | H=22 | N=2 | O=2 | S=1 \n| molecular_weight = 342.45 g/mol\n| SMILES = N#Cc2ccc(cc2)-c1ccc(C(C)CNS(=O)(=O)C(C)C)cc1\n| synonyms = <small>LY-404,187; ''N''-2-[4-(4-cyanophenyl)phenyl]propyl-2-propanesulfonamide</small>\n| StdInChI_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChI = 1S/C19H28N2O2S/c1-14(2)24(22,23)21-13-15(3)17-8-10-19(11-9-17)18-6-4-16(12-20)5-7-18/h4-7,14-15,17,19,21H,8-11,13H2,1-3H3\n| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChIKey = AIALBPYHYGYYRB-UHFFFAOYSA-N\n}}\n\n'''LY-404187''' is an [[AMPA receptor]] [[positive allosteric modulator]] which was developed by [[Eli Lilly and Company]].<ref name=\"pmid15864556\">{{ cite journal |vauthors=Jones N, O'Neill MJ, Tricklebank M, Libri V, Williams SC | title = Examining the Neural Targets of the AMPA Receptor Potentiator LY404187 in the Rat Brain Using Pharmacological Magnetic Resonance Imaging | journal = Psychopharmacology | year = 2005 | volume = 180 | issue = 4 | pages = 743\u2013751 | pmid = 15864556 | doi = 10.1007/s00213-005-2254-y }}</ref> It is a member of the [[biarylpropylsulfonamide]] class of AMPA receptor potentiators.<ref name=\"pmid16803862\">{{ cite journal |vauthors=Ryder JW, Falcone JF, Manro JR, Svensson KA, Merchant KM | title = Pharmacological Characterization of cGMP Regulation by the Biarylpropylsulfonamide Class of Positive, Allosteric Modulators of \u03b1-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors | journal = Journal of Pharmacology and Experimental Therapeutics | year = 2006 | volume = 319 | issue = 1 | pages = 293\u2013298 | pmid = 16803862 | doi = 10.1124/jpet.106.105734 | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=16803862 }}</ref>\n\nLY-404187 has been demonstrated to enhance cognitive function in animal studies, and has also shown effects suggesting [[antidepressant]] action as well as having possible application in the treatment of [[schizophrenia]], [[Parkinson's disease]] and [[ADHD]]. These effects appear to be mediated through multiple mechanisms of action secondary to AMPA receptor potentiation, with a prominent effect seen in research being increased levels of [[BDNF]] in the brain.<ref>{{ cite journal |vauthors=Quirk JC, Nisenbaum ES | title = LY404187: A Novel Positive Allosteric Modulator of AMPA Receptors | journal = CNS Drug Reviews | year = 2002 | volume = 8 | issue = 3 | pages = 255\u2013282 | doi = 10.1111/j.1527-3458.2002.tb00228.x | pmid = 12353058 | pmc = 6741690 }}</ref> It may therefore be continued on to human trials, although Eli Lilly has developed a whole family of biarylpropylsulfonamide derivatives and it is unclear at this stage which compound is most likely to be selected for further development.<ref>{{ cite journal |vauthors=O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES | title = AMPA Receptor Potentiators for the Treatment of CNS Disorders | journal = Current Drug Targets. CNS and Neurological Disorders | year = 2004 | volume = 3 | issue = 3 | pages = 181\u2013194 | doi = 10.2174/1568007043337508 | pmid = 15180479 }}</ref><ref>{{ cite journal |vauthors=O'Neill MJ, Witkin JM | title = AMPA Receptor Potentiators: Application for Depression and Parkinson's Disease | journal = Current Drug Targets | year = 2007 | volume = 8 | issue = 5 | pages = 603\u2013620 | doi = 10.2174/138945007780618517 | pmid = 17504104 }}</ref>\n\n==See also==\n* [[AMPA receptor positive allosteric modulator]]\n\n==References==\n{{Reflist|2}}\n\n{{Nootropics}}\n{{Ionotropic glutamate receptor modulators}}\n\n[[Category:AMPA receptor positive allosteric modulators]]\n[[Category:Eli Lilly and Company brands]]\n[[Category:Nitriles]]\n[[Category:Sulfonamides]]\n[[Category:Experimental drugs]]\n[[Category:Isopropyl compounds]]\n[[Category:Biphenyls]]\n\n{{nervous-system-drug-stub}}\n", "text_old": "{{Drugbox\n| Verifiedfields = changed\n| Watchedfields = changed\n| verifiedrevid = 449869240\n| IUPAC_name = ''N''-[2-(4'-cyanobiphenyl-4-yl)propyl]propane-2-sulfonamide\n| image = LY404187.png\n| width = 250px\n\n<!--Clinical data-->\n| tradename = \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B / C / D / X -->\n| pregnancy_category = \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = <!-- Schedule I -->\n| legal_UK = <!-- Class A -->\n| legal_US = Investigational New Drug\n| legal_status = \n| routes_of_administration = \n\n<!--Pharmacokinetic data-->\n| bioavailability = \n| protein_bound = \n| metabolism = \n| excretion = \n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 211311-95-4\n| ATC_prefix = none\n| ATC_suffix = \n| PubChem = \n| DrugBank_Ref = {{drugbankcite|correct|drugbank}}\n| DrugBank = \n| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = 18962921\n\n<!--Chemical data-->\n| C=19 | H=22 | N=2 | O=2 | S=1 \n| molecular_weight = 342.45 g/mol\n| SMILES = N#Cc2ccc(cc2)-c1ccc(C(C)CNS(=O)(=O)C(C)C)cc1\n| synonyms = <small>LY-404,187; ''N''-2-[4-(4-cyanophenyl)phenyl]propyl-2-propanesulfonamide</small>\n| StdInChI_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChI = 1S/C19H28N2O2S/c1-14(2)24(22,23)21-13-15(3)17-8-10-19(11-9-17)18-6-4-16(12-20)5-7-18/h4-7,14-15,17,19,21H,8-11,13H2,1-3H3\n| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChIKey = AIALBPYHYGYYRB-UHFFFAOYSA-N\n}}\n\n'''LY-404187''' is an [[AMPA receptor]] [[positive allosteric modulator]] which was developed by [[Eli Lilly and Company]].<ref name=\"pmid15864556\">{{ cite journal |vauthors=Jones N, O'Neill MJ, Tricklebank M, Libri V, Williams SC | title = Examining the Neural Targets of the AMPA Receptor Potentiator LY404187 in the Rat Brain Using Pharmacological Magnetic Resonance Imaging | journal = Psychopharmacology | year = 2005 | volume = 180 | issue = 4 | pages = 743\u2013751 | pmid = 15864556 | doi = 10.1007/s00213-005-2254-y }}</ref> It is a member of the [[biarylpropylsulfonamide]] class of AMPA receptor potentiators.<ref name=\"pmid16803862\">{{ cite journal |vauthors=Ryder JW, Falcone JF, Manro JR, Svensson KA, Merchant KM | title = Pharmacological Characterization of cGMP Regulation by the Biarylpropylsulfonamide Class of Positive, Allosteric Modulators of \u03b1-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors | journal = Journal of Pharmacology and Experimental Therapeutics | year = 2006 | volume = 319 | issue = 1 | pages = 293\u2013298 | pmid = 16803862 | doi = 10.1124/jpet.106.105734 | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=16803862 }}</ref>\n\nLY-404187 has been demonstrated to enhance cognitive function in animal studies, and has also shown effects suggesting [[antidepressant]] action as well as having possible application in the treatment of [[schizophrenia]], [[Parkinson's disease]] and [[ADHD]]. These effects appear to be mediated through multiple mechanisms of action secondary to AMPA receptor potentiation, with a prominent effect seen in research being increased levels of [[BDNF]] in the brain.<ref>{{ cite journal |vauthors=Quirk JC, Nisenbaum ES | title = LY404187: A Novel Positive Allosteric Modulator of AMPA Receptors | journal = CNS Drug Reviews | year = 2002 | volume = 8 | issue = 3 | pages = 255\u2013282 | doi = 10.1111/j.1527-3458.2002.tb00228.x | pmid = 12353058 | pmc = 6741690 }}</ref> It may therefore be continued on to human trials, although Eli Lilly has developed a whole family of biarylpropylsulfonamide derivatives and it is unclear at this stage which compound is most likely to be selected for further development.<ref>{{ cite journal |vauthors=O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES | title = AMPA Receptor Potentiators for the Treatment of CNS Disorders | journal = Current Drug Targets. CNS and Neurological Disorders | year = 2004 | volume = 3 | issue = 3 | pages = 181\u2013194 | doi = 10.2174/1568007043337508 | pmid = 15180479 }}</ref><ref>{{ cite journal |vauthors=O'Neill MJ, Witkin JM | title = AMPA Receptor Potentiators: Application for Depression and Parkinson's Disease | journal = Current Drug Targets | year = 2007 | volume = 8 | issue = 5 | pages = 603\u2013620 | doi = 10.2174/138945007780618517 | pmid = 17504104 }}</ref>\n\n==See also==\n* [[AMPA receptor positive allosteric modulator]]\n\n==References==\n{{Reflist|2}}\n\n{{Nootropics}}\n{{Ionotropic glutamate receptor modulators}}\n\n[[Category:AMPA receptor positive allosteric modulators]]\n[[Category:Eli Lilly and Company brands]]\n[[Category:Nitriles]]\n[[Category:Sulfonamides]]\n[[Category:Experimental drugs]]\n[[Category:Isopropyl compounds]]\n[[Category:Biphenyls]]\n\n{{nervous-system-drug-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/LY-404187"}
